August 23rd 2023
Verrica’s statement follows the FDA’s warning from June 1, 2023.
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Live Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease – Individualizing Vaccine Recommendations in Adolescent Populations
10/22/2023
Register Now!
Expert Illustrations and Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
Register Now!
2nd Annual International Congress on Pediatric Oncology
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Patient, Provider, and Caregiver Connection™: Challenges in Diagnosis and Management for Patients with ADHD During the COVID-19 Pandemic
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
FAQs in Peanut Allergy: Exploring Unanswered Questions Following Allergy Meeting Updates
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Mohs micrographic presents challenges in kids
November 25th 2020While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.
Dupilumab provides option for severe AD in younger children
October 21st 2020In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.
FDA grants priority review for dupilumab in pediatric AD
January 31st 2020The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.
Differences underlie pathology, indicating efficacy of atopic dermatitis treatments may vary
October 10th 2019Atopic dermatitis presents differently depending on whether the patient is an adult or child. This means that different treatments may be more effective in an adult than children and vice versa.
Steroid-free atopic dermatitis topical completes phase 4 trial
July 2nd 2019Crisaborole ointment, 2%, (Eucrisa, Pfizer) appears to be safe and effective in children aged three months to less than 24 months who have mild-to-moderate atopic dermatitis, according to results of a phase 4 trial released yesterday.
Current thinking on acne management
June 4th 2019Traditional treatments remain important parts of the dermatologist's armamentarium for acne management, but other drugs have begun to play a role, too. Meanwhile, research is offering new insight into the causes of acne. Stay up to date on the latest insight into acne's pathogenesis, evaluation and treatment. Participate in this forum.
A game-changer for children with atopic dermatitis
April 26th 2019“Pretty much, I couldn’t go about my normal life,” says Benjamin Sun about a life-altering eczema flare up at age 9, which left him out of school and bedridden for weeks. Until now, children like Sun didn’t have an effective, safe option for long-term disease control. Read how dupilumab changed his quality of life, and what it can do for your pediatric patients with uncontrolled moderate to severe atopic dermatitis.